Cogent Biosciences, Inc.
COGT
Peringkat dalam Saham
#3255
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Harga Saham
$31.37
Terakhir disinkronkan: 2026-10-20
Kapitalisasi Pasar
$5.44B
Perubahan (1 hari)
4.54%
Perubahan (1 tahun)
97.81%
Negara
US
Perdagangan Cogent Biosciences, Inc. (COGT)
Kategori
Healthcare
Riwayat pemecahan saham untuk Cogent Biosciences, Inc. (COGT)
Saham Cogent Biosciences, Inc. (simbol: COGT) telah mengalami total 1 kali pemecahan saham.
Pemecahan saham terbaru terjadi pada Nov 09, 2020.
Satu lembar saham COGT yang dibeli sebelum Nov 09, 2020 sekarang setara dengan 0.25 lembar saham COGT.
Pemecahan saham terbaru terjadi pada Nov 09, 2020.
Satu lembar saham COGT yang dibeli sebelum Nov 09, 2020 sekarang setara dengan 0.25 lembar saham COGT.
Daftar pemecahan saham
| Tahun | Pemecahan | Kelipatan | Kelipatan Kumulatif |
|---|---|---|---|
| 2020-11-09 | 1:4 | x0.25 | x0.25 |
Pemecahan saham untuk perusahaan sejenis atau pesaing
| Perusahaan | Jumlah pemecahan saham | Kelipatan Kumulatif | Negara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
